Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

An estimated 45,000 people have sued Merck, contending the drug caused heart attacks and strokes. Merck has spent more than $1 billion on legal fees during the last three years on Vioxx cases and has vowed to contest each lawsuit, The New York Times reported Tuesday.

Merck, the third-largest U.S. drug maker, is betting its aggressive resistance will reduce the number of cases and, ultimately, its liability, the Times reported. The result is a legal limbo in which even those who have won a case against Merck have yet to see any money because Merck immediately appeals, the newspaper said.

Estimates of Merck's liability, once as high as $25 billion, now is closer to $5 billion, corporate risk analysts told the Times.

Copyright 2007 by United Press International

Explore further: EU regulator: Morning-after pill OK for all women

add to favorites email to friend print save as pdf

Related Stories

Mass. doctor accused of faking pain pill data

Mar 11, 2009

(AP) -- A Massachusetts anesthesiologist has been accused of faking data for a dozen years in 21 published studies that suggested after-surgery benefits from painkillers including Vioxx and Celebrex.

When is a drug too risky to stay on the market?

Jun 30, 2010

(AP) -- The arthritis pill Vioxx was withdrawn but menopause hormones were not, even though both were tied to heart risks. A multiple sclerosis medicine was pulled and later allowed back on. So, when is a drug too risky to ...

FDA drug approvals mostly flat in 2009

Jan 05, 2010

(AP) -- Drug approvals from the Food and Drug Administration were flat last year compared with 2008 and warnings fell, even as the agency's new leadership struck a tougher stance on safety.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

13 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

13 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

14 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

14 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0